Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
551 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00466440 | A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | completed | Phase 2 | 108 | Eli Lilly and CompanyINDUSTRY | 3 | Nov 6, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT00538681 | Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo | terminated | Phase 2 | 35 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT00391118 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | completed | Phase 2 | 153 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT00542919 | A Study for Patients With Non-Hodgkin's Lymphomas | completed | Phase 2 | 57 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT00744991 | A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma | completed | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02923921 | Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer(Sequoia) | completed | Phase 3 | 567 | Eli Lilly and CompanyINDUSTRY | 13 | Oct 19, 2020 | clinicaltrials |
| NCT01432951 | A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma | completed | Phase 1 | 26 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02451930 | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | completed | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT02919696 | A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers | completed | Phase 1 | 26 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT00536939 | Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | terminated | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00586508 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | completed | Phase 2 | 81 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00414960 | A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers | completed | Phase 2 | 40 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 21, 2020 | clinicaltrials |
| NCT02079636 | A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | completed | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 11, 2020 | clinicaltrials |
| NCT03382912 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer(Cypress 2) | terminated | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT03283696 | A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 24 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 10, 2020 | clinicaltrials |
| NCT00718419 | A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma | completed | Phase 2 | 56 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 3, 2020 | clinicaltrials |
| NCT00267020 | Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 130 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT02014129 | A Study of LY2835219 in Japanese Participants With Advanced Cancer | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT00042666 | A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. | completed | Phase 2 | 55 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT00437294 | Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | terminated | Phase 2 | 86 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 10, 2020 | clinicaltrials |
| NCT00192114 | Enzastaurin for Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 6, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00436280 | Chemotherapy for Participants With Lymphoma | completed | Phase 2 | 68 | Eli Lilly and CompanyINDUSTRY | 3 | Aug 6, 2020 | clinicaltrials |
| NCT00437268 | A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | completed | Phase 2 | 26 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT00451178 | A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | completed | Phase 2 | 101 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT00612586 | Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer | completed | Phase 2 | 117 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 21, 2020 | clinicaltrials |
| NCT02411591 | A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 66 | Eli Lilly and CompanyINDUSTRY | 3 | Jul 9, 2020 | clinicaltrials |
| NCT00088205 | Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 4 | Jul 1, 2020 | clinicaltrials |
| NCT00530621 | Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer | completed | Phase 2 | 160 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 1, 2020 | clinicaltrials |
| NCT01388335 | A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin | completed | Phase 1 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT00309140 | An Open Label Study of Oral Enzastaurin in Participants With Cancer | completed | Phase 2 | 23 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02441946 | A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer(neoMONARCH) | completed | Phase 2 | 224 | Eli Lilly and CompanyINDUSTRY | 10 | Jun 17, 2020 | clinicaltrials |
| NCT02514551 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | completed | Phase 2 | 245 | Eli Lilly and CompanyINDUSTRY | 11 | Jun 17, 2020 | clinicaltrials |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT03955939 | A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | completed | Phase 1 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 1, 2020 | clinicaltrials |
| NCT02677116 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | completed | Phase 1 | 68 | Eli Lilly and CompanyINDUSTRY | 2 | May 20, 2020 | clinicaltrials |
| NCT03027284 | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT02529553 | A Study of LY3076226 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 25 | Eli Lilly and CompanyINDUSTRY | 2 | Apr 17, 2020 | clinicaltrials |
| NCT02124148 | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | completed | Phase 1 | 167 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 1, 2020 | clinicaltrials |
| NCT01393990 | A Study of LY2228820 in Participants With Advanced Cancer | completed | Phase 1 | 89 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 24, 2020 | clinicaltrials |
| NCT02735980 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 2 | 133 | Eli Lilly and CompanyINDUSTRY | 10 | Mar 17, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT04158700 | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 3 | Feb 19, 2020 | clinicaltrials |
| NCT02240433 | A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02102490 | A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread(MONARCH 1) | completed | Phase 2 | 132 | Eli Lilly and CompanyINDUSTRY | 4 | Jan 21, 2020 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT02326025 | A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | completed | Phase 1 | 49 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials